July 1 (UPI) --Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial, the company announced. The vaccine, called mRNA-1010, ...
The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in the waning days of the Biden administration. “While it is crucial that the ...
Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent higher for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback